Literature DB >> 19040607

Altered monocyte cyclo-oxygenase response in non-obese diabetic mice.

H Beyan1, L R Buckley, S A Bustin, N Yousaf, P Pozzilli, R D Leslie.   

Abstract

Monocytes infiltrate islets in non-obese diabetic (NOD) mice. Activated monocyte/macrophages express cyclo-oxygenase-2 (COX-2) promoting prostaglandin-E(2) (PGE(2)) secretion, while COX-1 expression is constitutive. We investigated in female NOD mice: (i) natural history of monocyte COX expression basally and following lipopolysaccharide (LPS) stimulation; (ii) impact of COX-2 specific inhibitor (Vioxx) on PGE(2), insulitis and diabetes. CD11b(+) monocytes were analysed for COX mRNA expression from NOD (n = 48) and C57BL/6 control (n = 18) mice. NOD mice were treated with either Vioxx (total dose 80 mg/kg) (n = 29) or methylcellulose as control (n = 29) administered by gavage at 4 weeks until diabetes developed or age 30 weeks. In all groups, basal monocyte COX mRNA and PGE(2) secretion were normal, while following LPS, after 5 weeks of age monocyte/macrophage COX-1 mRNA decreased (P < 0.01) and COX-2 mRNA increased (P < 0.01). However, diabetic NOD mice had reduced COX mRNA response (P = 0.03). Vioxx administration influenced neither PGE(2), insulitis nor diabetes. We demonstrate an isoform switch in monocyte/macrophage COX mRNA expression following LPS, which is altered in diabetic NOD mice as in human diabetes. However, Vioxx failed to affect insulitis or diabetes. We conclude that monocyte responses are altered in diabetic NOD mice but COX-2 expression is unlikely to be critical to disease risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040607      PMCID: PMC2675262          DOI: 10.1111/j.1365-2249.2008.03825.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Innate immunity in the etiopathology of autoimmunity.

Authors:  M Carroll
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

2.  Expression of cyclooxygenase-2 in intestinal goblet cells of pre-diabetic NOD mice.

Authors:  C Luo; V J O Laine; L Ylinen; T Teros; M Mäkinen; A Ristimäki; O Simell
Journal:  Acta Physiol Scand       Date:  2002-03

3.  Autoimmune type 1 diabetes: resolved and unresolved issues.

Authors:  A L Notkins; A Lernmark
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation.

Authors:  A Plesner; C J Greenbaum; L K Gaur; R K Ernst; A Lernmark
Journal:  Scand J Immunol       Date:  2002-11       Impact factor: 3.487

5.  Lipopolysaccharide regulates constitutive and inducible transcription factor activities differentially in vivo in the rat.

Authors:  X Ye; S F Liu
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

6.  BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice.

Authors:  S H Baik; I B Park; K M Choi; Y H Kim; N H Kim; S J Kim; G G Song; D S Choi
Journal:  Diabetes Res Clin Pract       Date:  1999-11       Impact factor: 5.602

7.  Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes.

Authors:  Huriya Beyan; Martin R Goodier; Niga S Nawroly; Mohammed I Hawa; Stephen A Bustin; William B Ogunkolade; Marco Londei; Nasim Yousaf; R David G Leslie
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

Review 8.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays.

Authors:  S A Bustin
Journal:  J Mol Endocrinol       Date:  2000-10       Impact factor: 5.098

9.  Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets.

Authors:  Y N Naumov; K S Bahjat; R Gausling; R Abraham; M A Exley; Y Koezuka; S B Balk; J L Strominger; M Clare-Salzer; S B Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

10.  Heat shock protein 60 elicits abnormal response in macrophages of diabetes-prone non-obese diabetic mice.

Authors:  Thure Adler; Hidehiko Akiyama; Christian Herder; Hubert Kolb; Volker Burkart
Journal:  Biochem Biophys Res Commun       Date:  2002-06-14       Impact factor: 3.575

View more
  2 in total

Review 1.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

2.  Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity.

Authors:  Markus Lundgren; Leigh Johnson Steed; Roy Tamura; Berglind Jonsdottir; Patricia Gesualdo; Claire Crouch; Maija Sjöberg; Gertie Hansson; William A Hagopian; Anette G Ziegler; Marian J Rewers; Åke Lernmark; Jorma Toppari; Jin-Xiong She; Beena Akolkar; Jeffrey P Krischer; Michael J Haller; Helena Elding Larsson
Journal:  BMC Pediatr       Date:  2017-05-16       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.